Status:
COMPLETED
Drug Use Investigation of COMIRNATY Intramuscular Injection
Lead Sponsor:
Pfizer
Conditions:
COVID-19
Eligibility:
All Genders
16+ years
Brief Summary
Post-marketing study, Chotor study of COMIRNATY vaccenees followed for 11months. Serious adverse events and COVID-19 observed during the follow-up period will be collected, and the long-term safety of...
Detailed Description
The healthcare professionals who are vaccinated with this product early after the marketing approval of this product (participants in the Investigation of Health Status of Recipients Vaccinated First ...
Eligibility Criteria
Inclusion
- Subjects who have participated in the Investigation of Health Status of Recipients Vaccinated First and have provided written consent to continue participation in this study.
Exclusion
- No exclusion criteria.
Key Trial Info
Start Date :
March 20 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 27 2023
Estimated Enrollment :
14570 Patients enrolled
Trial Details
Trial ID
NCT04815031
Start Date
March 20 2021
End Date
January 27 2023
Last Update
November 27 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
PfizerLocal Country Office
Tokyo, Japan, 1518589